Supplementation of n-3 polyunsaturated fatty acids for major depressive disorder: A randomized, double-blind, 12-week, placebo-controlled trial in Korea

Annals of Nutrition and Metabolism

Volumn 66, Issue 2-3, 2015, Pages 141-148

  Park, Yongsoon ^a   Park, Yoo Sin ^a   Kim, Seok Hyeon ^b   Oh, Dong Hoon ^b   Park, Yong Chon ^b  

^a Hanyang University   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

Author keywords

Korean; Major depressive disorder; n 3 polyunsaturated fatty acid; Randomized placebo controlled trial

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; SAFFLOWER OIL; OMEGA 6 FATTY ACID;

ADULT; ARTICLE; CALORIC INTAKE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ERYTHROCYTE LEVEL; FAT INTAKE; FEMALE; FISH; FOOD INTAKE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; KOREA; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; BLOOD; DIET THERAPY; MIDDLE AGED; TREATMENT OUTCOME;

CARTHAMUS TINCTORIUS;

ADULT; DEPRESSIVE DISORDER, MAJOR; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 84933034276     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000377640     Document Type: Article

References (41)

1. Arnow BA, Hunkeler EM, Blasey CM, Lee J, Constantino MJ, Fireman B, Kraemer HC, Dea R, Robinson R, Hayward C: Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006; 68: 262-268.
2. Sullivan PF, Neale MC, Kendler KS: Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552-1562.
3. Cross-national comparisons of the prevalences and correlates of mental disorders. WHO international consortium in psychiatric epidemiology. Bull World Health Organ 2000; 78: 413-426.
4. Korean National Health and Nutrition Examination Survey Report. Seoul, Korea, Institute for Health and Social Affairs Ministry of Health and Welfare, 2009.
5. Bodnar LM, Wisner KL: Nutrition and depression: implications for improving mental health among childbearing-aged women. Biol Psychiatry 2005; 58: 679-685.
6. Hibbeln JR: Fish consumption and major depression. Lancet 1998; 351: 1213.
7. Salem N Jr, Litman B, Kim HY, Gawrisch K: Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945-959.
8. Park Y, Moon HJ, Kim SH: N-3 polyunsaturated fatty acid consumption produces neurobiological effects associated with prevention of depression in rats after the forced swimming test. J Nutr Biochem 2012; 23: 924-928.
9. Baek D, Park Y: Association between erythrocyte n-3 polyunsaturated fatty acids and biomarkers of inflammation and oxidative stress in patients with and without depression. Prostaglandins Leukot Essent Fatty Acids 2013; 89: 291-296.
10. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY: Lowered omega3 n-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999; 85: 275-291.
11. Edwards R, Peet M, Shay J, Horrobin D: Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998; 48: 149-155.
12. McNamara RK, Jandacek R, Rider T, Tso P, Dwivedi Y, Pandey GN: Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord 2010; 126: 303-311.
13. Schiepers OJ, de Groot RH, Jolles J, van Boxtel MP: Plasma phospholipid fatty acid status and depressive symptoms: association only present in the clinical range. J Affect Disord 2009; 118: 209-214.
14. Baghai TC, Varallo-Bedarida G, Born C, Hafner S, Schule C, Eser D, Rupprecht R, Bondy B, von Schacky C: Major depressive disorder is associated with cardiovascular risk factors and low Omega-3 Index. J Clin Psychiatry 2011; 72: 1242-1247.
15. Lin PY, Huang SY, Su KP: A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 2010; 68: 140-147.
16. Colangelo LA, He K, Whooley MA, Daviglus ML, Liu K: Higher dietary intake of longchain omega-3 polyunsaturated fatty acids is inversely associated with depressive symptoms in women. Nutrition 2009; 25: 1011-1019.
17. Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, Lehtonen J, Vartiainen E: Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 2001; 52: 529-531.
18. Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P: Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord 2004; 82: 447-452.
19. Beydoun MA, Fanelli Kuczmarski MT, Beydoun HA, Hibbeln JR, Evans MK, Zonderman AB: Ω-3 fatty acid intakes are inversely related to elevated depressive symptoms among United States women. J Nutr 2013; 143: 1743-1752.
20. Park Y, Kim M, Baek D, Kim SH: Erythrocyte n-3 polyunsaturated fatty acid and seafood intake decrease the risk of depression: case-control study in Korea. Ann Nutr Metab 2012; 61: 25-31.
21. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drug. Arch Gen Psychiatry 2002; 59: 913-919.
22. Su KP, Huang SY, Chiu CC, Shen WW: Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13: 267-271.
23. Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477-479.
24. Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M: A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry 2009; 70: 1636-1644.
25. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ: A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003; 160: 996-998.
26. Silvers KM, Woolley CC, Hamilton FC, Watts PM, Watson RA: Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 211-218.
27. Grenyer BF, Crowe T, Meyer B, Owen AJ, Grigonis-Deane EM, Caputi P, Howe PR: Fish oil supplementation in the treatment of major depression: a randomised doubleblind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1393-1396.
28. Sublette ME, Ellis SP, Geant AL, Mann JJ: Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011; 72: 1577-1584.
29. Bloch MH, Hannestad J: Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 2012; 17: 1272-1282.
30. Cho MJ, Kim KH: Use of the Center for Epidemiologic Studies Depression (CES-D) scale in Korea. J Nerv Ment Dis 1998; 186: 304-310.
31. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, DC, American Psychiatric Press, 1994.
32. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
33. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
34. Guy W: ECDEU assessment manual for psychopharmacology; in US Department of Health and Human Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch. Rockville, Md., USA, 1976.
35. Harris WS, von Schacky C, Park Y: Standardizing methods for assessing omega-3 fatty acid biostatus; in McNamara RK (ed): The Omega-3 Fatty Acid Deficiency Syndrome. New York, Nova, 2012, pp 385-398.
36. Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, Drago F, Caraci F: Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014; 9:e96905.
37. Lesperance F, Frasure-Smith N, St-Andre E, Turecki G, Lesperance P, Wisniewski SR: The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 2011; 72: 1054-1062.
38. Appleton KM, Rogers PJ, Ness AR: Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010; 91: 757-770.
39. Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O: Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 1988; 23: 326-334.
40. Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21: 495-505.
41. Finnen MJ, Lovell CR: Purification and characterisation of phospholipase A2 from human epidermis. Biochem Soc Trans 1991; 19: 91S.